Soul JS, Bergin AM, Stopp C, et al. - Using a randomized, double‐blind, dose‐escalation design, researchers assessed the efficacy of bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard‐therapy control group. Eligible participants were postmenstrual neonates aged 33 to 44 weeks at risk or with seizures. Patients with electroencephalography‐confirmed seizures after ≥ 20 and < 40 mg/kg phenobarbital were randomly allocated to get additional phenobarbital with either placebo (control) or 0.1, 0.2, or 0.3mg/kg bumetanide (treatment). Although definitive evidence of efficacy needs confirmation in an appropriately powered phase 3 trial, this randomized, controlled, multicenter trial showed an additional lowering in seizure burden due to bumetanide over phenobarbital with no increase in serious adverse effects.